GlassScriptPhysician profile
Nor Darwish
NPI 1487031274
$3,577.88
in general payments reported to CMS, 2019-2025
25 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $676 · 2023: $1,835 · 2024: $562 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $904.87 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $395.93 | 2023-2024 | |
| Amgen INC. | $302.61 | 2022-2023 | Otezla, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $301.90 | 2022-2024 | Fasenra, Airsupra, Breztri |
| Intra-Sana Laboratories | $298.17 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Lilly USA, LLC | $232.19 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.63 | 2022-2023 | Xifaxan |
| Medtronic, INC. | $174.88 | 2021 | |
| Abbvie INC. | $148.24 | 2023-2025 | Qulipta, Vraylar, Ubrelvy |
| Currax Pharmaceuticals LLC | $125.37 | 2022-2025 | Contrave, Onzetra Xsail |
| Ardelyx, INC. | $74.75 | 2025 | Ibsrela |
| Exact Sciences Corporation | $71.60 | 2024-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $55.71 | 2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $44.21 | 2023 | |
| Merck Sharp & Dohme LLC | $30.96 | 2023 | Verquvo, Belsomra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $25.00 | 2024 | Visco-3 Sodium Hyaluronate |
| Shield Therapeutics INC | $24.82 | 2023 | Accrufer |
| Phathom Pharmaceuticals, INC. | $22.18 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $20.42 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.94 | 2024 | |
| Novo Nordisk INC | $17.63 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.65 | 2025 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $14.43 | 2025 | Spinosad, Natroba |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nor Darwish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.